279 related articles for article (PubMed ID: 36341440)
1. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1025608. PubMed ID: 36341440
[TBL] [Abstract][Full Text] [Related]
2. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
4. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
8. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
9. Gastric Cancer CAR T-cell Target Antigen ID'd.
Cancer Discov; 2021 Dec; 11(12):2954. PubMed ID: 34642170
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
11. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
[TBL] [Abstract][Full Text] [Related]
12. CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).
Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials.
Drougkas K; Karampinos K; Karavolias I; Gomatou G; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Kotteas E
J Gastrointest Cancer; 2024 May; ():. PubMed ID: 38695995
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
[TBL] [Abstract][Full Text] [Related]
15. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1082984. PubMed ID: 36618369
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells: engineered immune cells to treat brain cancers and beyond.
Huang Z; Dewanjee S; Chakraborty P; Jha NK; Dey A; Gangopadhyay M; Chen XY; Wang J; Jha SK
Mol Cancer; 2023 Jan; 22(1):22. PubMed ID: 36721153
[TBL] [Abstract][Full Text] [Related]
18. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
19. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]